MATINAS BIOPHARMA HOLDINGS, INC. Goodwill, Subsequent Recognition of Deferred Tax Asset
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Goodwill, Subsequent Recognition of Deferred Tax Asset of $48.19 million for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-15.
Discontinued › Notes
us-gaap:GoodwillSubsequentRecognitionOfDeferredTaxAsset · last filed 2016-08-15
- MATINAS BIOPHARMA HOLDINGS, INC. goodwill, subsequent recognition of deferred tax asset for the quarter ending 2016-06-30 was $48.14M.
- MATINAS BIOPHARMA HOLDINGS, INC. goodwill, subsequent recognition of deferred tax asset for the quarter ending 2016-03-31 was $48.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. goodwill, subsequent recognition of deferred tax asset for fiscal 2015 was $48.00K.
| Period end | Goodwill, Subsequent Recognition of Deferred Tax Asset 3 month | Goodwill, Subsequent Recognition of Deferred Tax Asset 6 month | Goodwill, Subsequent Recognition of Deferred Tax Asset 12 month |
|---|---|---|---|
| 2016-06-30 | $48.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $48.19M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $48.00K 10-Q · filed 2016-05-13 | ||
| 2015-12-31 | $48.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |